Five-Year Real-World Effectiveness and Drug Survival of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Phase III trials and their open-label extensions have established the efficacy of tildrakizumab in moderate-to-severe plaque psoriasis, but real-world evidence beyond 3 years of treatment is lacking. We assessed the long-term effectiveness, drug survival, and safety of tildrakizumab in routine clinical practice up to 5 years of follow-up. METHODS: A total of 1354 adult patients with moderate-to-severe psoriasis, treated with tildrakizumab for at least 16 weeks, were enrolled across 17 Italian Dermatology Units. Effectiveness was assessed as the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90, PASI 100, and absolute PASI ≤ 2 between week 16 and year 5. Drug survival was estimated by the Kaplan-Meier method, and multivariable logistic regression was used to identify baseline predictors of complete skin clearance. RESULTS: After 1 year of treatment, PASI 90, PASI 100, and PASI ≤ 2 were achieved by 74.0%, 57.2%, and 90.6% of patients, respectively, and responses were maintained through year 5 (87.3%, 76.2%, and 93.7%) in the 63 patients evaluable as observed. Overall drug survival was 92.0% at year 1 and 78.2% at year 5. A short disease duration was the only independent predictor of PASI 100, whereas obesity and cardiometabolic comorbidities did not impair response. No new safety signals emerged. CONCLUSIONS: In this 5-year real-world analysis, tildrakizumab maintained deep responses and high persistence across comorbid and difficult-to-treat subgroups, while short disease duration independently predicted complete clearance.
Source: Dermatology and Therapy
Authors: Mario Valenti, Sara Di Giulio, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Andrea Carugno, Emanuele C. Cozzani, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Piergiorgio Malagoli, Angelo V. Marzano, Luca Mastorino, Martina Maurelli, Matteo Megna, Alessandra Michelucci, Diego Orsini, Luca Potestio, Simone Ribero, Lidia Sacchelli, Massimo Travaglini, Emanuele Trovato, Nicola Zerbinati, Antonio Costanzo, Alessandra Narcisi, Luciano Ibba
Institutions: Humanitas University, IRCCS Humanitas Research Hospital, University of Campania "Luigi Vanvitelli", University of Bologna, Ospedale Policlinico San Martino, University of Genoa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Insubria, University of Pisa, IRCCS Policlinico San Donato, University of Verona, University of Messina, Azienda Ospedaliero-Universitaria di Modena, University of Bari Aldo Moro, University of Milan, University of Turin, University of Naples Federico II, San Gallicano Hospital, Ospedale A. Perrino, University of Siena
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $7,400
OpenAlex ID: W7234830990
